deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05190094

Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. (ICRG0201)

Multicenter, First-line Metastatic Open-label Prospective Phase II Trial Evaluating the Combination of Palbociclib (CDK 4/6 Inhibitor) and Hormone Therapy (Letrozole or Anastrozole) in Women With Luminal, HER2 Negative Advanced Breast Cancer: Evaluation of the Prediction of Individual Treatment Efficacy Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies (Quantum Optics).

Sponsor: International Cancer Research Group, United Arab Emirates

Conditions Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
Interventions Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)
Updated 9 times since 2022 Last updated: May 4, 2025 Started: Dec 20, 2022 Primary completion: Dec 31, 2025 Completion: Jun 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer, this trial is actively recruiting participants. The trial is conducted by International Cancer Research Group, United Arab Emirates and has accumulated 9 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshotNot Yet Recruiting~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshotNot Yet Recruiting~Apr 2023 – ~Nov 2023 · 7 months · monthly snapshotRecruiting~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshotRecruiting~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshotRecruiting~Mar 2025 – ~Jun 2025 · 3 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshotRecruiting

Change History

9 versions recorded

  1. Jun 2025 — Present [monthly]

    Recruiting PHASE2

  2. Mar 2025 — Jun 2025 [monthly]

    Recruiting PHASE2

  3. Sep 2024 — Mar 2025 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 4 earlier versions

  1. Nov 2023 — Apr 2024 [monthly]

    Recruiting PHASE2

  2. Apr 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  3. Sep 2022 — Apr 2023 [monthly]

    Not Yet Recruiting PHASE2

  4. Feb 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • International Cancer Research Group, United Arab Emirates
  • King Abdallah University for Science and Technology (KAUST), Thuwal, Saudi Arabia.
  • King Saud Medical City
  • Max-Planck-Institut für Quantenoptik (MPQ), and Faculty of Physics at Ludwig-Maximilians-Universität München (LMU), Garching, Germany
Data source: International Cancer Research Group, United Arab Emirates

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations